[4].XY Yang, JC Allen, EJ Aslim, et al. Patient-Reported outcomes of a phase II Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR) trial...
[4].XY Yang, JC Allen, EJ Aslim, et al. Patient-Reported outcomes of a phase II Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR) trial. EAU2020, abstract 1110 *此文仅用于向医学人士提供科学信息,不代表本平台观点...
“高危”前列腺癌的分类 Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. doi: 10.1038/nrclinonc.2014.68. Epub 2014 May 20. PMID: 24840073; PMCID: PMC4508854. 大约15%的前列腺癌患者被诊断出患...
High-risk prostate cancer with Gleason score 8-10 and PSA level 15 ng/ml treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;81:992-6.Fang LC, Merrick GS, Butler WM, et al. High-risk prostate cancer with Gleason score 8-10 and PSA level 615 ng/mL ...
[8] Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, ...
[8] Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.[J].Lancet Oncol.2019 May;20(5):686...
[8] Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.[J].Lancet Oncol.2019 May;20(5):686...
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the Americ
Stanczyk FZ, Skinner EC, Mertes S, Spahn MF, Lobo RA & Ross RK (1996) Alterations in circulating levels of androgens and PSA during treatment with Finasteride in men at high risk for prostate cancer. In Hormonal Carcinogenesis II, pp. 404- 407 [JJ Li, SA Li, J Gustafsson, S Nandi ...
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports the